ORIGINAL RESEARCH article

Front. Public Health

Sec. Health Economics

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1573000

This article is part of the Research TopicPublic Health Outcomes: The Role of Social Security Systems in Improving Residents' Health WelfareView all 61 articles

Trajectories of family functioning and financial toxicity in patients with glioma: a longitudinal study

Provisionally accepted
Yue  WuYue Wu1Yihao  WuYihao Wu2Botao  ZhouBotao Zhou1Rufei  DaiRufei Dai1*
  • 1Second Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
  • 2Xuzhou Central Hospital, Xuzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

Objective This study aims to investigate the longitudinal trajectories of family functioning and financial toxicity in glioma patients, while examining their predictive interrelationships, to establish evidence-based strategies for alleviating economic burden in neuro-oncology care. Methods: This prospective longitudinal cohort study enrolled 266 glioma patients from the Second Affiliated Hospital of Xuzhou Medical University and Xuzhou Central Hospital (January 2022–June 2024). Family functioning and financial toxicity were serially assessed at three timepoints: baseline (T1, initial diagnosis), 3-month follow-up (T2), and 6-month follow-up (T3). Structural equation modeling (SEM) framework incorporated cross-lagged panel analysis and latent growth curve modeling to examine temporal relationships.Results A total of 242 valid consecutive questionnaires were collected. The cross-lagged panel analysis demonstrated that the average family functioning level significantly and positively predicted subsequent financial toxicity at follow-up time points (β=0.478, P=0.01; β=0.463, P<0.001), while financial toxicity exhibited no significant longitudinal predictive effect on family functioning across subsequent assessments.The latent growth curve modeling revealed parallel declining trajectories: family functioning (slope [S]=-0.410, P<0.001) and financial toxicity (slope [S]=-0.102, P<0.001) both decreased significantly from T1 to T3. At baseline, family functioning showed positive correlation with financial toxicity scores (r=0.377, P=0.002). Initial family functioning level demonstrated dual regulatory effects: (1) negative auto-regulation (β=-0.352, P=0.007) and (2) inverse prediction of financial toxicity's developmental trajectory (β=-0.516, P=0.002). Crucially, the initial family functioning level exhibited compensatory effects on financial toxicity dynamics, showing negative coupling with its growth rate (β=-0.534, P<0.001). Conclusion Family functioning and financial toxicity of glioma patients can predict each other. The initial level of family functioning can positively predict the initial level of financial toxicity, the initial level of family functioning can negatively predict the development speed of itself and financial toxicity, and the development speed of family functioning can positively predict the development speed of financial toxicity.

Keywords: Glioma, family functioning, Financial toxicity, Development trajectory, Latent variable growth model, Cross-lag model

Received: 08 Feb 2025; Accepted: 12 May 2025.

Copyright: © 2025 Wu, Wu, Zhou and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Rufei Dai, Second Affiliated Hospital, Xuzhou Medical University, Xuzhou, 221006, Jiangsu Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.